LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

0.21 5

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.2

Max

0.23

Schlüsselkennzahlen
By Trading Economics
Einkommen	574K -47M
Verkäufe	3.2M 17M
EPS	-0.2
Gewinnspanne	-275.223
Angestellte	161
EBITDA	1.2M -45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2433.33% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-30M 49M
Vorheriger Eröffnungskurs	-4.79
Vorheriger Schlusskurs	0.21

Nachrichtenstimmung

By Acuity

50%

154 / 344 Ranking in Healthcare

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Mai 2026, 16:52 UTC

Wichtige Nachrichtenereignisse

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. Mai 2026, 23:57 UTC

Ergebnisse

Sociedad Quimica 1Q Rev $1.76B >SQM

26. Mai 2026, 23:57 UTC

Ergebnisse

Sociedad Quimica 1Q EPS $1.28 >SQM

26. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. Mai 2026, 21:54 UTC

Ergebnisse

Webco Industries 3Q EPS $11.61 >WEBC

26. Mai 2026, 21:54 UTC

Ergebnisse

Webco Industries 3Q Sales $179.6M >WEBC

26. Mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. Mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. Mai 2026, 20:58 UTC

Akquisitionen, Fusionen, Übernahmen

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. Mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. Mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. Mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. Mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. Mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. Mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. Mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. Mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. Mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. Mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. Mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. Mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. Mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. Mai 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Auto & Transport Roundup: Market Talk

26. Mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. Mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. Mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

2433.33% Vorteil

12-Monats-Prognose

Durchschnitt 5.32 USD 2433.33%

Hoch 15 USD

Tief 0.28 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Stimmung

By Acuity

154 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.